MARKET

IPHYF

IPHYF

Innate Pharma Marseille
OTCPK
2.250
NaN%
Closed 09:30 11/18 EST
OPEN
--
PREV CLOSE
2.250
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
2.250
52 WEEK LOW
1.580
MARKET CAP
251.33M
P/E (TTM)
-3.8560
1D
5D
1M
3M
1Y
5Y
1D
Innate Therapeutics: Buy Reiterated on Broad IPH4502 Responses; $7 Price Target Unchanged
TipRanks · 4h ago
Innate Pharma Reports Initial Phase 1 Data for IPH4502 at ENA 2026
TipRanks · 9h ago
Innate Pharma presents initial IPH4502 study data
TipRanks · 10h ago
Innate Pharma Announces November 18 IPH4502 Phase 1 Data Event
TipRanks · 6d ago
Innate Pharma to Host IPH4502 Phase 1 Data Event
TipRanks · 11/11 08:20
Buy Rating Reaffirmed as IPH4502, PACIFIC-9, and Lacutamab Catalysts Support Unchanged $9 Price Target
TipRanks · 11/06 14:04
Innate Pharma Reports Stronger Cash Position and Pipeline Progress
TipRanks · 11/05 07:47
Innate Pharma announces AstraZeneca updated timing for PACIFIC-9 data readout
TipRanks · 10/27 09:35
More
About IPHYF
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.

Webull offers Innate Pharma SA stock information, including OTCPK: IPHYF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IPHYF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IPHYF stock methods without spending real money on the virtual paper trading platform.